MiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells Through Regulating the Tumor Metabolism

PLoS ONE- United States

doi 10.1371/journal.pone.0152090

Full Text

Abstract

Available in

Date

Authors

Publisher

Public Library of Science (PLoS)

Related search

Active Glycolytic Metabolism in CD133(+) Hepatocellular Cancer Stem Cells: Regulation by MIR-122

Oncotarget
Oncology
2015English

Cx32 Reverses Epithelial-Mesenchymal Transition in Doxorubicin-Resistant Hepatocellular Carcinoma

Oncology Reports
MedicineCancer ResearchOncology
2017English

miR-122 Regulates Hepatic Lipid Metabolism and Tumor Suppression

Journal of Clinical Investigation
Medicine
2012English

MiR-139-5p Reverses CD44+/CD133+-associated Multidrug Resistance by Downregulating NOTCH1 in Colorectal Carcinoma Cells

Oncotarget
Oncology
2016English

Hepatocellular Carcinoma Cells Surviving Doxorubicin Treatment Exhibit Increased Migratory Potential and Resistance to Doxorubicin Re-Treatment In�vitro

Oncology Letters
Cancer ResearchOncology
2018English

Lamc1 Promotes the Warburg Effect in Hepatocellular Carcinoma Cells by Regulating PKM2 Expression Through AKT Pathway

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2019English

In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance Through Inhibition of Caspase-3–Mediated Apoptosis

Clinical Cancer Research
Cancer ResearchOncology
2017English

The Contribution of miR-122 to the Innate Immunity by Regulating Toll-Like Receptor 4 in Hepatoma Cells

BMC Gastroenterology
MedicineGastroenterology
2019English

808. Oncolytic Adenoviral Vector Targeted to Hepatocellular Carcinoma Expressing Low Levels of miR-122

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy